GlaxoSmithKline Plc (NYSE:GSK) To Offer Warranty On Strimvelis For Bubble Boy Disease

GlaxoSmithKline Plc (NYSE:GSK) has acquired European commercialization rights for one of the most expensive drugs in history. Strimvelis is the gene therapy for a rare medical condition dubbed ‘bubble boy disease.’ Given that the onetime treatment goes for a staggering $665,000, the drug maker plans to offer a money-back guarantee.

Story continues below

Strimvelis Warranty

According to the deal, the drug will have to deliver the desired impact or else a certain amount will be returned to patients upon administering the treatment. As it stands, Strimvelis is the first drug to come with a warranty, which understandably makes sense given its price tag. Money back guarantees on drugs are a common phenomenon in Italy, regulators having collected $220 million from 90 drugs last year alone.

Approved in Europe early this year, the drug is designed to deliver a missing gene to the bone marrow of children with ADA-SCID. The conditions, which can be fatal, is known to reduce the ability of patients to fight infections.

GlaxoSmithKline is to offer the drug only in Milan, a move that would require patients to travel from all over Europe to access it. Some of the pricing models already proposed for the drug include staggered payments over a period of years.

 Cheaper Option

Even though at $665,000 Strimvelis appears to be very expensive, it is relatively cheap compared to other gene therapies available. Costs for a bone marrow transplant from another person can reach highs of $1 million for the treatment of ADA-SCID. Enzyme injections, on the other hand, cost as much as $250,000 a year and must be continued.

The fact GlaxoSmithKline and Italy reached a price tag of below the $1 million mark for Strimvelis came as a surprise to many in the industry. In the near term, the drug maker will not be able to make a sizeable return from the drug given that it only expects an average of eight patients a year. However, there is hope that an entire platform will crop up from the drug to target other conditions thereby offering greater commercial opportunities in the long run.

An ad to help with our costs